Buy: Pfizer Stock

Potential buyers must weigh the value proposition against structural challenges that may limit near-term price appreciation:

: Pfizer remains a premier income stock, offering a 6.42% dividend yield . Management has reaffirmed its commitment to the dividend, declaring a $0.43 per share payout for the second quarter of 2026. While the payout ratio is elevated, management's cost-realignment program—targeting $7.2 billion in cumulative savings by 2027 —is intended to protect these cash returns. buy pfizer stock

: Pfizer anticipates a $1.5 billion revenue headwind in 2026 due to patent expirations, with these losses projected to accelerate to over $6 billion annually by 2028 . Potential buyers must weigh the value proposition against